In 2014, the US FDA approved addition of the anti-vascular endothelial growth factor (VEGF), angiogenesis inhibitor bevacizumab to chemotherapy for advanced cases of cervical cancer only [3]. Here, VEGFA is linked to cervical carcinoma.